Home Compare CSGP vs MRNA
Stock Comparison · Single-driver result

CoStar Group vs Moderna: Which Stock Looks Stronger in 2026?

CoStar leads structurally, with growth as the clearest single gap between the two profiles. Moderna still leads on profitability and valuation, which keeps the comparison from looking entirely one-sided. In the market, Moderna carries the stronger setup — intact trend against CoStar's broken trend. That leaves a split case: the structural lead stays with CoStar, but the market is not currently confirming it.

The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the S&P 500 universe, making them directly comparable.

Updated 2026-08-16

Growth still does most of the heavy lifting in this comparison. CoStar Group, Inc. leads by 9 points on the overall comparison score.

Trajectory Similarity
0.51
Loose match
Peer-set rank: #9
within CoStar Group, Inc.'s functional peer set

These two companies are linked by measured long-term financial trajectory similarity within the selected peer universe.

This is a looser trajectory match: still usable for comparison, but not especially tight.

Most of the shared profile comes through revenue stability.

Similarity drivers
revenue stability
What reduces the match
margin consistency
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
CSGP
CoStar Group, Inc.
25
Peer-Score
Signal qualityHigh
Peer basis: S&P 500
vs
MRNA
Moderna, Inc.
16
Peer-Score
Signal qualitylow
Peer basis: S&P 500

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The clearest separation appears in growth.

Dimension spread: CSGP vs MRNA Profitability 0 15 Stability 8 3 Valuation 10 30 Growth 100 8 CSGP MRNA
Gap Ranking
#1 Growth +92
#2 Valuation +20
#3 Profitability +15
#4 Stability +5
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for CSGP and MRNA Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer CSGPMRNA Relative valuation Structural strength

CoStar Group, Inc. still looks stronger overall, though current pricing looks more supportive for Moderna, Inc..

Valuation position uses peer-relative PE percentile (idx_pct_pe) and peer-relative valuation score where available.

Entry today — historical context

Where CSGP and MRNA each sit in their own 5-year price and valuation history.

BASED ON 5-YEAR HISTORY CSGP Lower · above norm 0th 50th 100th 32 pct gap MRNA Neutral · below norm 0th 50th 100th 4th 36th
Today CSGP sits in the lower portion of its own 5-year history (4th percentile), while MRNA sits higher in its own history (36th). Within each stock's own 5-year context, CSGP is at a historically more favourable entry position than MRNA. This reflects entry timing, not which company is structurally stronger — peer-relative analysis is a separate question addressed above.

Describes historical entry positioning only. Descriptive — not investment advice.

Relative Position vs Comparable Companies
Growth
CoStar Group, Inc. ranks near the top of the group on growth; Moderna, Inc. sits in the weaker half.
Valuation
Neither side looks especially strong on valuation, though Moderna, Inc. still ranks somewhat higher.
Growth — Dominant Gap
CSGP
100
MRNA
8
Gap+92in favour of CSGP

The current lead is backed by a stronger multi-year growth trajectory.

What keeps the gap from being one-sided

On the market side, Moderna carries the stronger trend while CoStar's trend has broken — the market setup does not confirm the structural advantage.

What this means for the comparison

Growth settles the comparison, while pricing and valuation keep the broader setup from looking fully aligned.

Explore full peer positioning in AssetNext

Break down the CSGP vs MRNA comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how CSGP and MRNA each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.